- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07560007
The Bleeding Assessment Tool (BAT) (BAT Protocol)
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This study focuses on improving how doctors evaluate children who may have a mild bleeding disorder, such as von Willebrand disease or platelet function disorders. Doctors already use a standardized bleeding questionnaire to record a child's bleeding symptoms, but this can be difficult in younger children who often haven't had major bleeding challenges like surgery or dental work. To address this, the researchers added a small number of family history questions to the existing tool to see if knowing about bleeding problems in relatives helps predict whether a child truly has a bleeding disorder.
The study reviews several years of existing medical records from children and young adults seen in a pediatric hematology clinic. By comparing the standard questionnaire with the expanded version that includes family history, the researchers want to see which approach more accurately identifies patients who go on to receive a confirmed diagnosis. The goal is to help clinicians decide more confidently who needs further testing and who does not, reducing unnecessary and costly lab work while improving diagnosis, especially for children under 8 years old, where bleeding symptoms alone may be misleading.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienorte
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- All individuals seen at CCHMC CBDI clinic for mild bleeding disorder with completed BAT+ at their new patient visit to Cincinnati Children's Hospital Medical Center (Base Campus or Liberty Campus) since 2019.
- If patient has multiple BAT+ scores will utilize the BAT+ score done at the new patient Hematology clinic CCHMC
Exclusion Criteria:
- Lack of BAT+ on new patient visit in outpatient setting to rule out mild
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
BAT CBDI patients
-All individuals seen at CCHMC CBDI clinic for mild bleeding disorder with completed BAT+ at their new patient visit to Cincinnati Children's Hospital Medical Center (Base Campus or Liberty Campus) since 2019.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
BAT+ Classification
Zeitfenster: From January 2019, through December 1, 2024
|
Dichotomous BAT classification (BAT+ vs BAT-) based on predefined age- and sex-specific BAT cutoffs.
|
From January 2019, through December 1, 2024
|
|
Bleeding Assessment Tool (BAT) Score
Zeitfenster: From January 2019, through December 1, 2024
|
Total BAT score calculated according to standardized criteria to quantify bleeding symptoms.
|
From January 2019, through December 1, 2024
|
|
Probability of Diagnosed Bleeding Disorder Based on BAT Score
Zeitfenster: From January 2019, through December 1, 2024
|
Predicted pretest probability of a confirmed bleeding disorder diagnosis (vWD, platelet function disorder, coagulation factor deficiency, or fibrinolytic disorder) estimated using logistic regression models with BAT score as a continuous predictor.
|
From January 2019, through December 1, 2024
|
|
Probability of Diagnosed Bleeding Disorder Based on BAT+ Status
Zeitfenster: From January 2019, through December 1, 2024
|
Predicted pretest probability of a confirmed bleeding disorder diagnosis estimated using logistic regression models with BAT+ classification as the primary predictor.
|
From January 2019, through December 1, 2024
|
|
Confirmed Bleeding Disorder Diagnosis by Category
Zeitfenster: From January 2019, through December 1, 2024
|
Final clinical diagnosis categorized as von Willebrand disease, platelet function disorder, coagulation factor deficiency, fibrinolytic disorder, or no bleeding disorder, using standardized diagnostic criteria.
|
From January 2019, through December 1, 2024
|
|
Diagnostic Accuracy of BAT
Zeitfenster: From January 2019, through December 1, 2024
|
Diagnostic accuracy of the Bleeding Assessment Tool (BAT) for identifying a confirmed bleeding disorder, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), using an initial cutoff score of ≥3.
Optimized cutoff scores will be reassessed using ROC analysis and Youden's Index.
|
From January 2019, through December 1, 2024
|
|
Diagnostic Accuracy of BAT+
Zeitfenster: From January 2019, through December 1, 2024
|
Diagnostic accuracy of the BAT+ classification for identifying a confirmed bleeding disorder, including sensitivity, specificity, PPV, and NPV, using an initial cutoff score of ≥6.
Optimized cutoffs will be reassessed using ROC analysis and Youden's Index.
|
From January 2019, through December 1, 2024
|
|
Likelihood Ratios for BAT
Zeitfenster: From January 2019, through December 1, 2024
|
Positive likelihood ratio for BAT at the initial cutoff score of ≥3 and at optimized cutoffs derived from ROC analysis.
|
From January 2019, through December 1, 2024
|
|
Likelihood Ratios for BAT+
Zeitfenster: From January 2019, through December 1, 2024
|
Positive likelihood ratio for BAT+ at the initial cutoff score of ≥6 and at optimized cutoffs derived from ROC analysis.
|
From January 2019, through December 1, 2024
|
|
Area Under the ROC Curve (AUC) for BAT
Zeitfenster: From January 2019, through December 1, 2024
|
Area under the receiver operating characteristic (ROC) curve for BAT scores derived from logistic regression models discriminating confirmed bleeding disorder diagnosis (yes/no).
|
From January 2019, through December 1, 2024
|
|
Area Under the ROC Curve (AUC) for BAT+
Zeitfenster: From January 2019, through December 1, 2024
|
Area under the ROC curve for BAT+ classification derived from logistic regression models discriminating confirmed bleeding disorder diagnosis (yes/no).
|
From January 2019, through December 1, 2024
|
|
Optimized BAT Cutoff Score
Zeitfenster: From January 2019, through December 1, 2024
|
Optimized BAT cutoff score identified using Youden's Index based on ROC curve analysis.
|
From January 2019, through December 1, 2024
|
|
Optimized BAT+ Cutoff Score
Zeitfenster: From January 2019, through December 1, 2024
|
Optimized BAT+ cutoff identified using Youden's Index based on ROC curve analysis.
|
From January 2019, through December 1, 2024
|
Mitarbeiter und Ermittler
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, Neunert C, Lillicrap D; ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010 Sep;8(9):2063-5. doi: 10.1111/j.1538-7836.2010.03975.x. No abstract available.
- Castaman G, Eikenboom JC, Bertina RM, Rodeghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost. 1999 Sep;82(3):1065-70.
- O'Brien SH. An update on pediatric bleeding disorders: bleeding scores, benign joint hypermobility, and platelet function testing in the evaluation of the child with bleeding symptoms. Am J Hematol. 2012 May;87 Suppl 1:S40-4. doi: 10.1002/ajh.23157. Epub 2012 Mar 28.
- Hayward CP. Diagnosis and management of mild bleeding disorders. Hematology Am Soc Hematol Educ Program. 2005:423-8. doi: 10.1182/asheducation-2005.1.423.
- Sramek A, Eikenboom JC, Briet E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern Med. 1995 Jul 10;155(13):1409-15.
- Rodeghiero F, Tosetto A, Castaman G. How to estimate bleeding risk in mild bleeding disorders. J Thromb Haemost. 2007 Jul;5 Suppl 1:157-66. doi: 10.1111/j.1538-7836.2007.02520.x.
- Bui J, Martyres D, James PD, Grabell J, Wu J, Steele M, Silva M, Rand ML, Blanchette VS, Barrowman N, Klaassen RJ. Validation of the school age self-administered pediatric bleeding questionnaire (Self-PBQ) in children aged 8-12 years. Pediatr Blood Cancer. 2019 Jun;66(6):e27709. doi: 10.1002/pbc.27709. Epub 2019 Mar 22.
- Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost. 2009 Aug;7(8):1418-21. doi: 10.1111/j.1538-7836.2009.03499.x. Epub 2009 May 30. No abstract available.
- Rydz N, James PD. The evolution and value of bleeding assessment tools. J Thromb Haemost. 2012 Nov;10(11):2223-9. doi: 10.1111/j.1538-7836.2012.04923.x.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Genetische Krankheiten, angeboren
- Hämatologische Erkrankungen
- Blutgerinnungsstörungen
- Hämorrhagische Störungen
- Erkrankungen der Blutplättchen
- Blutgerinnungsstörungen, vererbt
- Gerinnungsproteinstörungen
- Angeborene, erbliche und neonatale Krankheiten und Anomalien
- Hämische und lymphatische Krankheiten
- Hämostasestörungen
- von Willebrand -Krankheiten
Andere Studien-ID-Nummern
- BAT Protocol: 2025-0160
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .